Anthony Johnson, Goldfinch Bio CEO (Goldfinch via YouTube)

Gilead-part­nered Goldfinch Bio lands $100M as it piv­ots to clin­i­cal stage biotech

A year af­ter land­ing $109 mil­lion in cash for an ear­ly-stage dis­cov­ery deal with Gilead, Goldfinch Bio has scored a sim­i­lar boun­ty from in­vestors …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.